A study to assess the efficacy, safety, and tolerability of a drug named RO7239361 in boys with Duchenne muscular dystrophy
Goal of this study
To treat Duchenne muscular dystrophy.
Duchenne muscular dystrophy (DMD) is a genetic disease due to the absence of a protein called dystrophin. DMD is characterized by progressive muscle degeneration and weakness, and is due to deterioration of muscle cells which are important for body movement. This study will investigate the efficacy, safety and tolerability of a drug named RO7239361 in patients with DMD. RO7239361 will be given to the patient subcutaneously which means through injection under the skin for a period of 48 weeks.
Who can participate in this study?
Patients who have been diagnosed with Duchenne muscular dystrophy and who are between 6 and 11 years of age may be eligible to participate in this study. This study accepts boys and does not accept healthy volunteers.
Important: Additional eligibility criteria apply and the patient’s record will be verified by the study doctor (with the patient’s approval) to confirm eligibility.
ClinicalTrials.gov Identifier: NCT03039686
To know if you're eligible to participate in this trial, please fill-up the form below and we will contact you shortly.